FOSUN PHARMA (02196) surged over 6% again, rising 5.51% to HK$21.06 at the time of writing, with turnover reaching HK$299 million. On the news front, FOSUN PHARMA recently announced that its controlling subsidiary Fosun Pharma Industry has entered into a License Agreement with Expedition, granting Expedition the rights to develop, manufacture, and commercialize the investigational product XH-S004 globally, excluding mainland China, Hong Kong, and Macau. Expedition will pay up to $120 million in non-refundable upfront and development and regulatory milestone payments, and up to $525 million in sales milestone payments based on annual net sales of the licensed product in the licensed territory. According to a research report, DPP-1 inhibitor drugs have significant market potential. Currently, the company's XH-S004 drug for treating non-cystic fibrosis bronchiectasis is in Phase II clinical trials in China, while its application for treating chronic obstructive pulmonary disease is in Phase Ib clinical trials in China. The company has invested a cumulative 72 million RMB in research and development. This overseas licensing of the company's innovative product, receiving recognition from foreign innovative drug investment and development teams, supports the revaluation of the company's innovative drug pipeline under development.